Glycopyrronium tosylate

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

Retrieved on: 
Wednesday, September 6, 2023
Agreement, Hyperhidrosis, Marketing, Food and Drug Administration, Dermatology, Patient, Glycopyrronium tosylate, Amendment, Food, Pharmaceutical industry

Pursuant to the terms of the Agreement, Journey Medical granted Maruho an exclusive license to develop and commercialize Qbrexza® (Rapifort® / DRM04 / glycopyrronium tosylate hydrate) for the treatment of hyperhidrosis, in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos (the “Territory”).

Key Points: 
  • Pursuant to the terms of the Agreement, Journey Medical granted Maruho an exclusive license to develop and commercialize Qbrexza® (Rapifort® / DRM04 / glycopyrronium tosylate hydrate) for the treatment of hyperhidrosis, in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos (the “Territory”).
  • Under the terms of the Agreement, Journey Medical will receive a $19 million nonrefundable upfront payment.
  • Maruho is responsible for all development and commercialization costs for the program throughout the Territory.
  • Additionally, in conjunction with the new license grant, Journey Medical and Maruho have also entered into an amendment of their existing license agreement that grants Maruho exclusive rights to Qbrexza (Rapifort) in Japan (the “Amendment”).

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 22, 2023
News, EWB, PPR, Marketing, Clinical trial, NDA, Journey, GAAP, Minocycline, Security, EBITDA, IGA, New Çeltek events, Investment, Research, Adjustment, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Rosacea, Food, Communications satellite, Pharmaceutical industry, Glycopyrronium tosylate

SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • ET
    SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • In addition, all products were unfavorably impacted by higher gross-to-net adjustments compared to the first quarter of 2022.
  • In January 2023, Journey Medical completed enrollment in its DFD-29 Phase 3 clinical program for the treatment of PPR and achieved the “Last Patient Out” milestone in May 2023.
  • Journey Medical management will conduct a conference call and audio webcast on May 22, 2023, at 4:30 p.m.

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Wednesday, March 29, 2023
Molecule, News, Rosacea, IPO, Food, Teva, Regulation of tobacco by the U.S. Food and Drug Administration, Tobacco Master Settlement Agreement, Clinical trial, NDA, Pharmacokinetics, Journey, GAAP, Asset purchase agreement, Minocycline, IGA, EBITDA, Acquisition, Patent, New Çeltek events, Growth, Federation, Research, Adjustment, FDA, Therapy, Pharmaceutical industry, Video game, Cryptocurrency, Dietary supplement, Generic drug, Health, Glycopyrronium tosylate

SCOTTSDALE, Ariz., March 29, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • ET
    SCOTTSDALE, Ariz., March 29, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2022.
  • Selling, general and administrative expenses were $59.5 million for the full year 2022, compared to $39.8 million for 2021.
  • In January 2023, Journey Medical completed enrollment in its DFD-29 Phase 3 clinical program for the treatment of papulopustular rosacea.
  • Journey Medical is entitled to receive royalties and commercial milestones from Maruho’s sales of Rapifort, which was commercially launched in May 2022.